ESHRE guideline: ovarian stimulation for IVF/ICSI†
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
STUDY QUESTION: What is the recommended management of ovarian stimulation, based on the best available evidence in the literature? SUMMARY ANSWER: The guideline development group formulated 84 recommendations answering 18 key questions on ovarian stimulation. WHAT IS KNOWN ALREADY: Ovarian stimulation for IVF/ICSI has been discussed briefly in the National Institute for Health and Care Excellence guideline on fertility problems, and the Royal Australian and New Zealand College of Obstetricians and Gynaecologist has published a statement on ovarian stimulation in assisted reproduction. There are, to our knowledge, no evidence-based guidelines dedicated to the process of ovarian stimulation. STUDY DESIGN, SIZE, DURATION: The guideline was developed according to the structured methodology for development of ESHRE guidelines. After formulation of key questions by a group of experts, literature searches and assessments were performed. Papers published up to 8 November 2018 and written in English were included. The critical outcomes for this guideline were efficacy in terms of cumulative live birth rate per started cycle or live birth rate per started cycle, as well as safety in terms of the rate of occurrence of moderate and/or severe ovarian hyperstimulation syndrome (OHSS). PARTICIPANTS/MATERIALS, SETTING, METHODS: Based on the collected evidence, recommendations were formulated and discussed until consensus was reached within the guideline group. A stakeholder review was organized after finalization of the draft. The final version was approved by the guideline group and the ESHRE Executive Committee. MAIN RESULTS AND THE ROLE OF CHANCE: The guideline provides 84 recommendations: 7 recommendations on pre-stimulation management, 40 recommendations on LH suppression and gonadotrophin stimulation, 11 recommendations on monitoring during ovarian stimulation, 18 recommendations on triggering of final oocyte maturation and luteal support and 8 recommendations on the prevention of OHSS. These include 61 evidence-based recommendations—of which only 21 were formulated as strong recommendations—and 19 good practice points and 4 research-only recommendations. The guideline includes a strong recommendation for the use of either antral follicle count or anti-Müllerian hormone (instead of other ovarian reserve tests) to predict high and poor response to ovarian stimulation. The guideline also includes a strong recommendation for the use of the GnRH antagonist protocol over the GnRH agonist protocols in the general IVF/ICSI population, based on the comparable efficacy and higher safety. For predicted poor responders, GnRH antagonists and GnRH agonists are equally recommended. With regards to hormone pre-treatment and other adjuvant treatments (metformin, growth hormone (GH), testosterone, dehydroepiandrosterone, aspirin and sildenafil), the guideline group concluded that none are recommended for increasing efficacy or safety. LIMITATIONS, REASON FOR CAUTION: Several newer interventions are not well studied yet. For most of these interventions, a recommendation against the intervention or a research-only recommendation was formulated based on insufficient evidence. Future studies may require these recommendations to be revised. WIDER IMPLICATIONS OF THE FINDINGS: The guideline provides clinicians with clear advice on best practice in ovarian stimulation, based on the best evidence available. In addition, a list of research recommendations is provided to promote further studies in ovarian stimulation. STUDY FUNDING/COMPETING INTEREST(S): The guideline was developed and funded by ESHRE, covering expenses associated with the guideline meetings, with the literature searches and with the dissemination of the guideline. The guideline group members did not receive payment. F.B. reports research grant from Ferring and consulting fees from Merck, Ferring, Gedeon Richter and speaker’s fees from Merck. N.P. reports research grants from Ferring, MSD, Roche Diagnositics, Theramex and Besins Healthcare; consulting fees from MSD, Ferring and IBSA; and speaker’s fees from Ferring, MSD, Merck Serono, IBSA, Theramex, Besins Healthcare, Gedeon Richter and Roche Diagnostics. A.L.M reports research grants from Ferring, MSD, IBSA, Merck Serono, Gedeon Richter and TEVA and consulting fees from Roche, Beckman-Coulter. G.G. reports consulting fees from MSD, Ferring, Merck Serono, IBSA, Finox, Theramex, Gedeon-Richter, Glycotope, Abbott, Vitrolife, Biosilu, ReprodWissen, Obseva and PregLem and speaker’s fees from MSD, Ferring, Merck Serono, IBSA, Finox, TEVA, Gedeon Richter, Glycotope, Abbott, Vitrolife and Biosilu. E.B. reports research grants from Gedeon Richter; consulting and speaker’s fees from MSD, Ferring, Abbot, Gedeon Richter, Merck Serono, Roche Diagnostics and IBSA; and ownership interest from IVI-RMS Valencia. P.H. reports research grants from Gedeon Richter, Merck, IBSA and Ferring and speaker’s fees from MSD, IBSA, Merck and Gedeon Richter. J.U. reports speaker’s fees from IBSA and Ferring. N.M. reports research grants from MSD, Merck and IBSA; consulting fees from MSD, Merck, IBSA and Ferring and speaker’s fees from MSD, Merck, IBSA, Gedeon Richter and Theramex. M.G. reports speaker’s fees from Merck Serono, Ferring, Gedeon Richter and MSD. S.K.S. reports speaker’s fees from Merck, MSD, Ferring and Pharmasure. E.K. reports speaker’s fees from Merck Serono, Angellini Pharma and MSD. M.K. reports speaker’s fees from Ferring. T.T. reports speaker’s fees from Merck, MSD and MLD. The other authors report no conflicts of interest. Disclaimer: This guideline represents the views of ESHRE, which were achieved after careful consideration of the scientific evidence available at the time of preparation. In the absence of scientific evidence on certain aspects, a consensus between the relevant ESHRE stakeholders has been obtained. Adherence to these clinical practice guidelines does not guarantee a successful or specific outcome, nor does it establish a standard of care. Clinical practice guidelines do not replace the need for application of clinical judgment to each individual presentation, nor variations based on locality and facility type. ESHRE makes no warranty, express or implied, regarding the clinical practice guidelines and specifically excludes any warranties of merchantability and fitness for a particular use or purpose. (Full disclaimer available at www.eshre.eu/guidelines.) †ESHRE Pages content is not externally peer reviewed. The manuscript has been approved by the Executive Committee of ESHRE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
Hao (2015) · doi:10.1002/14651858 · Cited by 11,321
Ferraretti, A. P., La Marca, A., Fauser, B. C. J. M., Tarlatzis, B., Nargund, G., Gianaroli, L., & on behalf of the ESHRE working group on Poor Ovarian Response Definition (2011) · Human Reproduction · doi:10.1093/humrep/der092 · Cited by 1,882
Self-citationAndrews, J., Guyatt, G., Oxman, A. D., Alderson, P., Dahm, P., Falck-Ytter, Y., Nasser, M., Meerpohl, J., Post, P. N., Kunz, R., et al. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.03.013 · Cited by 1,416
The international glossary on infertility and fertility care, 2017
Zegers-Hochschild, F., Adamson, G. D., Dyer, S., Racowsky, C., de Mouzon, J., Sokol, R., Rienzi, L., Sunde, A., Schmidt, L., Cooke, I. D., et al. (2017) · Human Reproduction · doi:10.1093/humrep/dex234 · Cited by 1,320
A systematic review of tests predicting ovarian reserve and IVF outcome
Broekmans, F. J., Kwee, J., Hendriks, D. J., Mol, B. W., & Lambalk, C. B. (2006) · Human Reproduction Update · doi:10.1093/humupd/dml034 · Cited by 1,258
Self-citationBaart, E. B., Martini, E., Eijkemans, M. J., Van Opstal, D., Beckers, N. G. M., Verhoeff, A., Macklon, N. S., & Fauser, B. C. J. M. (2007) · Human Reproduction · doi:10.1093/humrep/del484 · Cited by 609
Endometrial thickness and pregnancy rates after IVF: a systematic review and meta-analysis
Kasius, A., Smit, J. G., Torrance, H. L., Eijkemans, M. J. C., Mol, B. W., Opmeer, B. C., & Broekmans, F. J. M. (2014) · Human Reproduction Update · doi:10.1093/humupd/dmu011 · Cited by 608
Self-citationGonadotrophin-releasing hormone antagonists for assisted reproductive technology
Al-Inany, H. G., Youssef, M. A., Ayeleke, R. O., Brown, J., Lam, W. S., & Broekmans, F. J. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001750.pub4 · Cited by 600
Self-citationLuteal phase support for assisted reproduction cycles
van der Linden, M., Buckingham, K., Farquhar, C., Kremer, J. A., & Metwally, M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009154.pub3 · Cited by 467
Broer, S. L., van Disseldorp, J., Broeze, K. A., Dolleman, M., Opmeer, B. C., Bossuyt, P., Eijkemans, M. J. C., Mol, B.-W. J., Broekmans, F. J. M., on behalf of the IMPORT study group, et al. (2013) · Human Reproduction Update · doi:10.1093/humupd/dms041 · Cited by 457
Self-citationYoussef, M. A., Van der Veen, F., Al-Inany, H. G., Mochtar, M. H., Griesinger, G., Nagi Mohesen, M., Aboulfoutouh, I., & van Wely, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008046.pub4 · Cited by 426
Self-citationEngmann, L., DiLuigi, A., Schmidt, D., Nulsen, J., Maier, D., & Benadiva, C. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.02.002 · Cited by 422
Kuang, Y., Chen, Q., Fu, Y., Wang, Y., Hong, Q., Lyu, Q., Ai, A., & Shoham, Z. (2015) · Fertility and Sterility · doi:10.1016/j.fertnstert.2015.03.022 · Cited by 410
Lambalk, C. B., Banga, F. R., Huirne, J. A., Toftager, M., Pinborg, A., Homburg, R., van der Veen, F., & van Wely, M. (2017) · Human Reproduction Update · doi:10.1093/humupd/dmx017 · Cited by 404
Papanikolaou, E. G., Pozzobon, C., Kolibianakis, E. M., Camus, M., Tournaye, H., Fatemi, H. M., Van Steirteghem, A., & Devroey, P. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.07.1292 · Cited by 336
Self-citationSteward, R. G., Lan, L., Shah, A. A., Yeh, J. S., Price, T. M., Goldfarb, J. M., & Muasher, S. J. (2014) · Fertility and Sterility · doi:10.1016/j.fertnstert.2013.12.026 · Cited by 336
Hohmann, F. P., Macklon, N. S., & Fauser, B. C. J. M. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020788 · Cited by 281
Distinction between early and late ovarian hyperstimulation syndrome
Mathur, R. S., Akande, A. V., Keay, S. D., Hunt, L. P., & Jenkins, J. M. (2000) · Fertility and Sterility · doi:10.1016/s0015-0282(00)00492-1 · Cited by 281
Fresh versus frozen embryo transfers in assisted reproduction
Wong, K. M., van Wely, M., Mol, F., Repping, S., & Mastenbroek, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011184.pub2 · Cited by 274
Self-citationKuang, Y., Chen, Q., Hong, Q., Lyu, Q., Ai, A., Fu, Y., & Shoham, Z. (2014) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2014.08.009 · Cited by 272
The poor responder in IVF: is the prognosis always poor? A systematic review
Oudendijk, J. F., Yarde, F., Eijkemans, M. J. C., Broekmans, F. J. M., & Broer, S. L. (2012) · Human Reproduction Update · doi:10.1093/humupd/dmr037 · Cited by 230
Self-citationMetformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome
Tso, L. O., Costello, M. F., Albuquerque, L. E. T., Andriolo, R. B., & Macedo, C. R. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006105.pub3 · Cited by 228
Humaidan, P., Polyzos, N. P., Alsbjerg, B., Erb, K., Mikkelsen, A. L., Elbaek, H. O., Papanikolaou, E. G., & Andersen, C. Y. (2013) · Human Reproduction · doi:10.1093/humrep/det249 · Cited by 213
Self-citationvan Wely, M., Kwan, I., Burt, A. L., Thomas, J., Vail, A., Van der Veen, F., & Al-Inany, H. G. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005354.pub2 · Cited by 210
Broer, S. L., Dólleman, M., van Disseldorp, J., Broeze, K. A., Opmeer, B. C., Bossuyt, P. M. M., Eijkemans, M. J. C., Mol, B. W., Broekmans, F. J. M., Broer, S. L., et al. (2013) · Fertility and Sterility · doi:10.1016/j.fertnstert.2013.04.024 · Cited by 187
Self-citationGrowth hormone for in vitro fertilization
Duffy, J. M., Ahmad, G., Mohiyiddeen, L., Nardo, L. G., & Watson, A. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000099.pub3 · Cited by 172
Babayof, R., Margalioth, E. J., Huleihel, M., Amash, A., Zylber-Haran, E., Gal, M., Brooks, B., Mimoni, T., & Eldar‐Geva, T. (2006) · Human Reproduction · doi:10.1093/humrep/dei475 · Cited by 170
Rodgers, R. J., Reid, G., Koch, J., Deans, R., Ledger, W. J., Friedlander, M. L., Gilchrist, R. B., Walters, K. A., & Abbott, J. A. (2017) · Human Reproduction · doi:10.1093/humrep/dex027 · Cited by 157
Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction
Nagels, H. E., Rishworth, J. R., Siristatidis, C. S., & Kroon, B. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009749.pub2 · Cited by 156
van Hooff, M. H. A., Alberda, A. T., Huisman, G. J., Zeilmaker, G. H., & Leerentveld, R. A. (1993) · Human Reproduction · doi:10.1093/oxfordjournals.humrep.a138053 · Cited by 147
Farquhar, C. M., Rombauts, L. J. F., Kremer, J. A. M., Lethaby, A. E., & Ayeleke, R. O. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006109.pub3 · Cited by 143
Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Siristatidis, C. S., Gibreel, A., Basios, G., Maheshwari, A., & Bhattacharya, S. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006919.pub4 · Cited by 126
Vaiarelli, A., Cimadomo, D., Trabucco, E., Vallefuoco, R., Buffo, L., Dusi, L., Fiorini, F., Barnocchi, N., Bulletti, F. M., Rienzi, L. F., et al. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00317 · Cited by 124
Aspirin for in vitro fertilisation
Siristatidis, C. S., Basios, G., Pergialiotis, V., & Vogiatzi, P. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004832.pub4 · Cited by 113
Youssef, M. A. F. M., Abou-Setta, A. M., & Lam, W. S. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003719.pub4 · Cited by 99
Li, X., Wang, L., Lv, F., Huang, X., Wang, L., Pan, Y., & Zhang, X. (2017) · Medicine · doi:10.1097/md.0000000000006443 · Cited by 98
Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI)
Kwan, I., Bhattacharya, S., Kang, A., & Woolner, A. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005289.pub3 · Cited by 95
Griesinger, G., Verweij, P. J. M., Gates, D. F., Devroey, P., Gordon, K., Stegmann, B. J., & Tarlatzis, B. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149615 · Cited by 95
Self-citationWestergaard, L. G., Erb, K., Laursen, S., Rasmussen, P. E., & Rex, S. (1996) · Human Reproduction · doi:10.1093/oxfordjournals.humrep.a019357 · Cited by 75
Aromatase inhibitors in ovarian stimulation for IVF/ICSI: a pilot study
Verpoest, W., Kolibianakis, E. M., Papanikolaou, E. G. E., Smitz, J. E. J., Steirteghem, A. V., & Devroey, P. (2006) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)60611-6 · Cited by 73
Self-citationChen, Q., Wang, Y., Sun, L., Zhang, S., Chai, W., Hong, Q., Long, H., Wang, L., Lyu, Q., & Kuang, Y. (2017) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-017-0291-0 · Cited by 62
Pacchiarotti, A., Sbracia, M., Frega, A., Selman, H. A., Rinaldi, L., & Pacchiarotti, A. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2010.04.035 · Cited by 61
Liu, C., Jiang, H., Zhang, W., & Yin, H. (2017) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2017.08.019 · Cited by 59
Jacob, S., Brewer, C., Tang, T., Picton, H., Barth, J. H., & Balen, A. H. (2016) · Human Reproduction · doi:10.1093/humrep/dew268 · Cited by 55
Barbosa, M. W. P., Valadares, N. P. B., Barbosa, A., Amaral, A., Iglesias, J. R., Nastri, C. O., Martins, W. P., & Nakagawa, H. M. (2018) · JBRA · doi:10.5935/1518-0557.20180018 · Cited by 49
Bechtejew, T. N., de Nadai, M. N., Nastri, C. O., & Martins, W. P. (2017) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.17442 · Cited by 47
Random-start ovarian stimulation in women desiring elective cryopreservation of oocytes
Pereira, N., Voskuilen-Gonzalez, A., Hancock, K., Lekovich, J. P., Schattman, G. L., & Rosenwaks, Z. (2017) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2017.06.002 · Cited by 43
Fresh versus frozen embryo transfers for assisted reproduction
- (2018) · Kazan medical journal · doi:10.17816/kmj8434 · Cited by 39
Mukherjee, S., Sharma, S., & Chakravarty, B. (2012) · Journal of Human Reproductive Sciences · doi:10.4103/0974-1208.101014 · Cited by 36
Ebrahimi, M., Akbari-Asbagh, F., & Ghalandar-Attar, M. (2017) · International Journal of Reproductive BioMedicine (IJRM) · doi:10.29252/ijrm.15.2.101 · Cited by 35
Luteal phase ovarian stimulation for poor ovarian responders
Zhang, W., Wang, M., Wang, S., Bao, H., Qu, Q., Zhang, N., & Hao, C. (2018) · JBRA · doi:10.5935/1518-0557.20180045 · Cited by 32
Strategies for the management of OHSS: Results from freezing-all cycles
Borges, E., Braga, D. P. A. F., Setti, A. S., Vingris, L. S., Figueira, R. C. S., & Iaconelli, A. (2016) · JBRA · doi:10.5935/1518-0557.20160003 · Cited by 28
Zhang, Q., Guo, X. M., & Li, Y. (2016) · Reproduction Fertility and Development · doi:10.1071/rd16020 · Cited by 21
Manual for ESHRE guideline development
Vermeulen, N., Clef, N. L., D’Angelo, A., Tilleman, K., Veleva, Z., & Nelen, W. L. D. M. (2017) · Työväentutkimus Vuosikirja · Cited by 20
Self-citationAtaalla, W. M., Elhamid, T. A., & Elhalwagy, A. (2016) · Middle East Fertility Society Journal · doi:10.1016/j.mefs.2015.12.004 · Cited by 17
Jiang, S., & Kuang, Y. (2017) · Medicine · doi:10.1097/md.0000000000007540 · Cited by 10
Evaluation of low-dose letrozole addition to ovulation induction in IVF.
Yaşa, C., Baştu, E., Dural, Ö., Çelik, E., & Ergun, B. (2013) · PubMed · Cited by 9
Hamdi, K., Farzadi, L., Ghasemzadeh, A., Navali, N., Atashkhoei, S., Pia, H., Shahnazi, V., Fattahi, A., Bahrami‐Asl, Z., Sepasi, F., et al. (2017) · International Journal of Women s Health and Reproduction Sciences · doi:10.15296/ijwhr.2018.31 · Cited by 5
Saleh, S. E., Ismail, M. T., & Elshmaa, N. S. (2013) · Middle East Fertility Society Journal · doi:10.1016/j.mefs.2013.01.009 · Cited by 1
Cited by
ESHRE guideline: female fertility preservation
The ESHRE Guideline Group on Female Fertility Preservation, Anderson, R. A., Amant, F., Braat, D., D'Angelo, A., Chuva de Sousa Lopes, S. M., Demeestere, I., Dwek, S., Frith, L., Lambertini, M., et al. (2020) · Human Reproduction Open · doi:10.1093/hropen/hoaa052 · Cited by 748
Self-citationFertility Preservation in People With Cancer: ASCO Guideline Update
Su, H. I., Lacchetti, C., Letourneau, J., Partridge, A. H., Qamar, R., Quinn, G. P., Reinecke, J., Smith, J. F., Tesch, M., Wallace, W. H., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02782 · Cited by 278
Metadata
- Authors
- The ESHRE Guideline Group on Ovarian Stimulation, Bosch, E., Broer, S., Griesinger, G., Grynberg, M., Humaidan, P., Kolibianakis, E., Kunicki, M., La Marca, A., Lainas, G., Le Clef, N., Massin, N., Mastenbroek, S., Polyzos, N., Sunkara, S. K., Timeva, T., Töyli, M., Urbancsek, J., Vermeulen, N., & Broekmans, F.
- Venue
- Human Reproduction Open
- Publisher
- Oxford University Press (OUP)
- Published
- 2020
- Volume
- 2020
- Issue
- 2
- Pages
- hoaa009-hoaa009
- ISSN
- 2399-3529 (ISSN-L)
- OpenAlex
- W3023643850
- Cited by
- 543
- References
- 60
- FWCI
- 49.00
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.